Abstract
Background/Objectives:
The objective of this study was to investigate whether serum triglycerides (S-TG), cholesterol, blood pressure and waist/height ratio are risk factors for Parkinson’s disease (PD).
Subjects and Methods:
A population-based sample within the Northern Sweden Health and Disease Study (NSHDS) was used in this study (n=101 790 subjects). Cases with PD were identified prospectively in a community-based study of idiopathic Parkinsonism in the period 2004–2009 in the county of Västerbotten in northern Sweden. The case database obtained was crosslinked to the NSHDS. Eighty-four of 147 patients with PD had visited the primary health care 2–8 years before diagnosis for participation in the NSHDS. For each case, four referents from the NSHDS population were selected, matched for sex, age, year of health survey, subcohort and geographic area.
Results:
Cases had lower mean S-TG levels (P=0.007). After stratification for sex, the lower S-TG remained significant for men (P=0.006) but not for women (P=0.450), and these were confirmed by the conditional logistic regression for all cases, none adjusted (hazard ratio (HR): 0.65; 95% confidence interval (CI): 0.42, 0.99) and after adjusting for age, body mass index (BMI) and physical activity (HR: 0.61; 95% CI: 0.39, 0.96). Systolic blood pressure (SBP) was negatively associated with PD risk after adjustments for age, BMI and physical activity (HR: 0.98; 95% CI: 0.97–0.99). Smoking and former smoking were associated with a reduced risk for PD.
Conclusions:
We found lower S-TG and SBP 2–8 years before a diagnosis of PD. Smoking was confirmed to be negatively associated with PD, whereas recreational activity indicates a risk for women.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C et al. Vascular contributions to cognitive impairment and dementia: a statement for health care professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 2672–2713.
Kaffashian S, Dugravor A, Elbaz A, Shipley MJ, Sabia S, Kivimäki M et al. Predicting cognitive decline: a dementia risk score vs the Framingham vascular risk scores. Neurology 2013; 80: 1300–1306.
Aarsland D, Kvaløy JT, Andersen K, Larsen JP, Tang MX, Lolk A et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007; 254: 38–45.
Linder J, Stenlund H, Forsgren L . Incidence of Parkinson’s disease and parkinsonism in northern Sweden: a population-based study. Mov Disord 2010; 25: 341–348.
Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007; 64: 990–997.
Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J . Body mass index and the risk of Parkinson disease. Neurology 2006; 67: 1955–1959.
Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J . Total cholesterol and the risk of Parkinson disease. Neurology 2008; 70: 1972–1979.
Qiu C, Hu G, Kivipelto M, Marder KS, Nelson LM, Rocca WA et al. Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study. Hypertension 2011; 57: 1094–1100.
De Lau LM, Koudstaal PJ, Hofman A, Breteler MB . Serum cholesterol levels and the risk of Parkinsons disease. Am J Epidemiol 2006; 164: 998–1002.
Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H . Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 47–52.
Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F . Reduced risk factors for vascular disorders in Parkinson disease patients: a case–control study. Stroke 2006; 37: 1184–1188.
Savica R, Grossardt BR, Ahlskog JE, Rocca WA . Metabolic markers or conditions preceding Parkinson's disease: a case–control study. Mov Disord 2012; 27: 974–979.
Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH et al. Nonlinear progression of Parkinson Disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005; 62: 378–382.
Gibb WR, Lees AJ . The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–752.
Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort—evaluation of risk factors and their interactions. Scand J Public Health Suppl 2003; 61: 18–24.
Norberg M, Blomstedt Y, Lönnberg G, Nyström L, Stenlund H, Wall S et al. Community participation and sustainability—evidence over 25 years in the Västerbotten Intervention Programme. Glob Health Action 2012; 5: 1–9.
Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ . Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopaPET. J Neurol Neurosurg Psychiatry 1998; 64: 314–319.
Simon KC, Chen H, Schwarzschild M, Ascherio A . Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688–1695.
Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology 2002; 59: 1051–1057.
Ragonese P, D'Amelio M, Callari G, Di Benedetto N, Palmeri B, Mazzola MA et al. Body mass index does not change before Parkinson's disease onset. Eur J Neurol 2008; 15: 965–968.
Hernán MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A . Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 2001; 50: 780–786.
Håglin LM, Törnkvist B, Bäckman LO . High serum phosphate and triglyceride levels in smoking women and men with CVD risk and type 2 diabetes. Diabetol Metab Syndr 2014; 6: 39.
Vlajinac H, Sipetic S, Marinkovic J, Ratkov I, Maksimovic J, Dzoljic E et al. The stressful life events and Parkinson's disease: a case–control study. Stress Health 2013; 29: 50–55.
Sasco AJ, Paffenbarger RS Jr, Gendre I, Wing AL . The role of physical exercise in the occurrence of Parkinson's disease. Arch Neurol 1992; 49: 360–365.
Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A . Physical activity and the risk of Parkinsons disease. Neurology 2005; 64: 664–669.
Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ et al. Recreational physical activity and risk of Parkinson's disease. Mov Disord 2008; 23: 69–74.
Tsekouras YE, Magkos F, Kellas Y, Basioukas KN, Kavouras SA, Sidossis LS . High-intensity interval aerobic training reduces hepatic very low-density lipoprotein-triglyceride secretion rate in men. Am J Physiol Endocrinol Metab 2008; 295: E851–E858.
Acknowledgements
This work was supported by grants from The Swedish Parkinson Foundation (Svenska Parkinsonstiftelsen), Swedish Parkinson Foundation, Neuro Sweden and Västerbotten County Council (ALF).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest
Rights and permissions
About this article
Cite this article
Vikdahl, M., Bäckman, L., Johansson, I. et al. Cardiovascular risk factors and the risk of Parkinson’s disease. Eur J Clin Nutr 69, 729–733 (2015). https://doi.org/10.1038/ejcn.2014.259
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2014.259
This article is cited by
-
A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson’s disease
Lipids in Health and Disease (2020)
-
Longitudinal analysis of premotor anthropometric and serological markers of Parkinson’s disease
Scientific Reports (2020)
-
Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases
Cellular and Molecular Neurobiology (2020)